ATLANTA, Aug. 18 (HSMN NewsFeed) — CryoLife, Inc., (NYSE: CRY ) an implantable biological medical device and cardiovascular tissue processing company, today announced the first three implantations of the CryoPatch(R) SG pulmonary human cardiac patch sin…
Devices, Cardiology
CryoLife, CryoPatch, SynerGraft, cardiac patch

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material”
Leave a Comment